O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma.
about
Transcriptional regulation of human DNA repair genes following genotoxic stress: trigger mechanisms, inducible responses and genotoxic adaptationMarked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedulesTemozolomide in patients with advanced cancer: phase I and pharmacokinetic study.A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma.MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome.Drug-resistance in human melanoma.O6-alkylguanine-DNA alkyltransferase: role in carcinogenesis and chemotherapy.The history and future of chemotherapy for melanoma.O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomideTemozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations.Heterogeneity of O6-alkylguanine DNA-alkyltransferase expression in human breast tumours.O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma.Temozolomide for the treatment of metastatic melanomaThe therapeutic potential of O6-alkylguanine DNA alkyltransferase inhibitors.The PARP inhibitor ABT-888 potentiates dacarbazine-induced cell death in carcinoids.Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article.Chemotherapy Resistance Mechanisms in Advanced Skin Cancer.Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects.Regional treatment strategies for in-transit melanoma metastasis.Systemic therapy for advanced pancreatic neuroendocrine tumorsWhat is the role of chemotherapy in the treatment of melanoma?B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells.Immunohistochemical analysis of O(6)-methylguanine-DNA methyltransferase in human melanoma in comparison with skin squamous cell carcinoma.Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells.Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53.NICE verdict on Temozolomide: where next?Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study.
P2860
Q27026117-860EC8C1-5EDE-45CB-A5F8-EB333A5087F6Q33347264-A604717C-1E46-4331-BF95-15F03F544416Q33358701-11864D10-8AE6-40A8-9D6F-40667B880A3CQ33384102-5D081245-B39A-426C-AD55-9A12EABF3ACDQ34253639-0A9F6B19-1F65-44A4-A184-F0D7C6867075Q34321923-04391352-F284-4342-8CD2-215CFCE5891EQ34561510-75D21723-081D-428C-97B4-542CDE47D7F2Q34608084-980EB2DF-3E99-499C-B84D-C5E7AD2E4D66Q35001754-2A960E4E-7AE2-45D5-ABF5-43065638D47FQ36545498-372473CC-A398-44CC-A357-9A3C2A84720CQ36611825-304925FC-2853-4FED-B650-FAD827A3DD2EQ36616482-50AD0B8B-732D-4D3D-86F4-E0FDCB5C28F9Q36644575-77072228-5650-4613-97D2-5B4202563613Q36671260-36B2ECAF-E0B4-4ED5-A731-866EF43AF1B9Q36852256-722FB80D-157A-4D57-BB23-B3D7E684CE0BQ36964700-AA432CCB-0E1B-4476-A020-4CCD193A1E1AQ37372483-A51BB853-6623-444E-8D08-E3406CF2A270Q37454341-F0B4F761-E34B-407F-914A-7E8635FA8D30Q37736532-7EE5D484-2724-415D-8857-9D4E7DFBDDCDQ37766550-EAB5693B-35CE-48CE-A6ED-A35B6730F618Q37812815-D6E8C48E-D647-4383-9867-83D998135373Q38079854-DA68A7F7-6B16-4AF0-A87D-4C86997DFB87Q38193716-72B11779-903F-4C0A-AF2C-2293E0F2B2A1Q38923467-BA4F014E-8340-4DF0-910A-824FA9ACC572Q39457448-5056B42B-7767-4A4E-A93F-41F05D53EE4DQ39908793-5FFC9BFF-94FA-429E-8695-C184D9FA8037Q43188994-67234924-A104-4798-8788-BE12CEA16E5EQ43217464-C80CC52F-E230-4B5F-B288-2B5DA9BBF5CEQ48278842-39D5B69B-FA76-4E95-90F7-023698F9DC4E
P2860
O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
O6-methylguanine-DNA methyltra ...... e to temozolomide in melanoma.
@ast
O6-methylguanine-DNA methyltra ...... e to temozolomide in melanoma.
@en
type
label
O6-methylguanine-DNA methyltra ...... e to temozolomide in melanoma.
@ast
O6-methylguanine-DNA methyltra ...... e to temozolomide in melanoma.
@en
prefLabel
O6-methylguanine-DNA methyltra ...... e to temozolomide in melanoma.
@ast
O6-methylguanine-DNA methyltra ...... e to temozolomide in melanoma.
@en
P2093
P2860
P356
P1476
O6-methylguanine-DNA methyltra ...... e to temozolomide in melanoma.
@en
P2093
A H Calvert
D R Newell
E S Newlands
G P Margison
M H Brampton
M R Middleton
P2860
P2888
P304
P356
10.1038/BJC.1998.654
P407
P577
1998-11-01T00:00:00Z